Screener
AOCI at other companies
Other financials
Where this comes from
Reported directly by Amneal Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax.
The source filing: Amneal Pharmaceuticals, Inc.’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 5:19 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001723128-26-000031
FAQ
- What is Amneal Pharmaceuticals, Inc.'s AOCI?
- Amneal Pharmaceuticals, Inc. (AMRX) reported AOCI of -$100.67M in Q2 2026.
- How has Amneal Pharmaceuticals, Inc.'s AOCI changed year-over-year?
- Amneal Pharmaceuticals, Inc.'s AOCI decreased by 3.3% year-over-year, from -$97.43M to -$100.67M.
- What is the long-term trend for Amneal Pharmaceuticals, Inc.'s AOCI?
- Over 5 years (2020 to 2025), Amneal Pharmaceuticals, Inc.'s AOCI has grown at a 21.8% compound annual growth rate (CAGR), from -$41.32M to -$110.73M.
- What does AOCI mean?
- Accumulated gains and losses bypassing the income statement — unrealized investment gains/losses, currency translation, pension adjustments, and hedge results.
Ask your AI about Amneal Pharmaceuticals, Inc.'s aoci.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude